
Job: Associate Director/Principal Scientist, CMC Analytical Chemistry
Location: Thousand Oaks, CA or San Francisco, CA
Position type: Full Time
Reports to: Director of Analytical Chemistry
Organization Overview
Latigo Biotherapeutics (LatigoBio) is a private, early-stage biotechnology company discovering and developing the next generation of non-opioid medicines for pain and pain-related syndromes to transform the lives of patients. Latigo has a robust pipeline, is well-funded by blue chip investors, and has a highly successful management team and Board of Directors. The company was founded in 2019 and is based in Thousand Oaks, CA. We are science-based, data-driven, patient-focused, and forward-thinking.
Position Summary
Latigo is searching for an Associate Director/Principal Scientist, CMC Analytical Chemistry. Reporting to the Director of Analytical Chemistry, the candidate will manage preclinical to clinical analytical development activities and oversee the testing and release of drug substance and drug product at contract manufacturers/service providers. The role is responsible for the development, validation and implementation of QC methods for drug substance, drug product, intermediates, starting materials, excipients, and packaging materials at contract manufacturers.
Additional responsibilities include reference standard qualification and management, establishment of specifications, oversight of stability programs and the active management and documentation of data. The selected candidate will also work collaboratively with Quality Assurance to assess laboratory conformance with cGMPs, and with CMC Regulatory Affairs to author Module 3 sections of CTD regulatory submissions and written responses to regulatory authorities.
Primary Responsibilities
Qualifications and Requirements
Location
Thousand Oaks, California
Department
CMC
Employment Type
Full-Time
Minimum Experience
Senior Manager/Supervisor
Compensation
$180,000 - $200,000
Latigo Biotherapeutics Inc., headquartered in Thousand Oaks, CA, is a privately held clinical-stage biotechnology company developing best-in-class non-opioid pain medicines that target the fundamental mechanism of pain transduction. The company’s proprietary, in-house technology generates novel drugs against targets validated by human genetics using the most advanced artificial intelligence, machine learning, structure-based, and knowledge-based design techniques to optimize potency and selectivity. The company is backed by top-tier investors, including Westlake Village BioPartners, 5AM Ventures, Foresite Capital, and Corner Ventures.
Take the next step in your career journey